Background: Parkinson disease (PD) impairs gait, balance, and quality of life, and wearable devices have been proposed to support rehabilitation, but evidence for their clinical efficacy remains uncertain. Objective: This study aimed to evaluate, within the International Classification of Functioning, Disability, and Health (ICF) framework, the effects of wearable-device interventions on gait performance, balance, and health-related quality of life in people with PD by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: We searched PubMed, Web of Science, Cochrane Library, Embase, and ClinicalTrials.gov from inception to November 18, 2025, for RCTs in people with PD comparing wearable-device interventions with control conditions. We used Hartung-Knapp random-effects models to pool mean differences (MDs) or standardized mean differences (SMDs) and reported 95% prediction intervals when ≥3 studies were pooled. Risk of bias was assessed using the Cochrane Risk of Bias (RoB) tool, and certainty of evidence was rated using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Results: Nine RCTs involving 260 participants were included. Wearable devices produced a small improvement in stride length (MD 0.10 meter, 95% CI 0.03-0.17), but there was no clear benefit for the 10-Meter Walk Test time (MD 0.04 second, 95% CI –0.06 to 0.15). Double support time showed no reduction (MD –1.59% gait cycle, 95% CI –3.79 to 0.61). Freezing of gait (Freezing of Gait Questionnaire [FOG-Q] and New Freezing of Gait Questionnaire [NFOG-Q]) did not significantly improve (SMD –0.24, 95% CI –0.72 to 0.24). Motor severity (Unified Parkinson Disease Rating Scale Part III [UPDRS III]) showed a small, nonsignificant trend favoring wearable devices (MD –2.16 points, 95% CI –4.39 to 0.07). For balance, pooled results from the Berg Balance Scale (BBS), Mini Balance Evaluation Systems Test (Mini-BESTest), and Performance-Oriented Mobility Assessment Balance Subscale (POMA balance) suggested a borderline effect (SMD 0.48, 95% CI –0.02 to 0.98). Wearable devices did not meaningfully improve Parkinson Disease Questionnaire (PDQ) scores (SMD –0.28, 95% CI –0.74 to 0.17), EQ-5D utility (MD 0.10, 95% CI –0.24 to 0.44), or Falls Efficacy Scale–International (FES-I) scores (MD –0.04, 95% CI –1.10 to 1.02). Prediction intervals frequently crossed the null, suggesting effects may vary by setting and population. Conclusions: Wearable device interventions for Parkinson disease produced a small improvement on average in stride length, with no consistent benefits for other gait outcomes, balance, or patient-centered outcomes. By integrating ICF mapping with Hartung-Knapp meta-analysis, prediction intervals, and GRADE, and avoiding pooling of conceptually distinct gait measures used in prior reviews, this review clarifies where evidence is most consistent, supports using wearables as adjuncts to rehabilitation, and underscores the need for larger, longer RCTs with standardized outcomes to determine who benefits and how to implement them. Trial Registration: PROSPERO CRD42024585686; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024585686

Chronic ankle instability (CAI) is associated with altered sensorimotor control during jump–landing, but open biomechanics datasets rarely combine clinically relevant cohorts with controlled visual perturbations. We present a multimodal drop vertical jump dataset from 28 young adults (12 with CAI and 16 non-CAI controls). Participants completed one real-world 30-cm condition and four virtual-reality (VR) visual-height conditions (0, 10, 30 and 50 cm), while physical drop height remained 30 cm. Kinematic data and ground reaction forces were synchronously recorded for all participants, and bilateral surface electromyography (EMG) from six lower-limb muscles is available for 17 participants (6 with CAI and 11 non-CAI controls). The EMG acquisition protocol was designed to capture task-evoked muscle activity during high-velocity drop vertical jumps, with separate maximum voluntary isometric contraction (MVIC) assessments outside its scope. The released EMG signals were band-pass filtered by the acquisition hardware but remain unrectified and unnormalized. Participant-specific MVIC reference measurements are not available for amplitude normalization. Motion-capture data were acquired using a 38-marker Plug-in-Gait–compatible set. The resource contains labeled and quality-checked C3D files, format-converted TRC, MOT, and ASCII files, anonymized metadata, an OpenSim model, and a MATLAB kinematic-processing script. Metadata include group classification, limb dominance and affected side, demographics, anthropometrics, body composition, and bilateral lower-limb morphometrics. The dataset can support secondary analyses of landing biomechanics, neuromuscular responses to visual-height perturbations, and musculoskeletal-modeling workflows.

BACKGROUND Parkinson disease (PD) impairs gait, balance, and quality of life, and wearable devices have been proposed to support rehabilitation, but evidence for their clinical efficacy remains uncertain. OBJECTIVE This study aimed to evaluate, within the International Classification of Functioning, Disability, and Health (ICF) framework, the effects of wearable-device interventions on gait performance, balance, and health-related quality of life in people with PD by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs). METHODS We searched PubMed, Web of Science, Cochrane Library, Embase, and ClinicalTrials.gov from inception to November 18, 2025, for RCTs in people with PD comparing wearable-device interventions with control conditions. We used Hartung-Knapp random-effects models to pool mean differences (MDs) or standardized mean differences (SMDs) and reported 95% prediction intervals when ≥3 studies were pooled. Risk of bias was assessed using the Cochrane Risk of Bias (RoB) tool, and certainty of evidence was rated using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). RESULTS Nine RCTs involving 260 participants were included. Wearable devices produced a small improvement in stride length (MD 0.10 meter, 95% CI 0.03-0.17), but there was no clear benefit for the 10-Meter Walk Test time (MD 0.04 second, 95% CI –0.06 to 0.15). Double support time showed no reduction (MD –1.59% gait cycle, 95% CI –3.79 to 0.61). Freezing of gait (Freezing of Gait Questionnaire [FOG-Q] and New Freezing of Gait Questionnaire [NFOG-Q]) did not significantly improve (SMD –0.24, 95% CI –0.72 to 0.24). Motor severity (Unified Parkinson Disease Rating Scale Part III [UPDRS III]) showed a small, nonsignificant trend favoring wearable devices (MD –2.16 points, 95% CI –4.39 to 0.07). For balance, pooled results from the Berg Balance Scale (BBS), Mini Balance Evaluation Systems Test (Mini-BESTest), and Performance-Oriented Mobility Assessment Balance Subscale (POMA balance) suggested a borderline effect (SMD 0.48, 95% CI –0.02 to 0.98). Wearable devices did not meaningfully improve Parkinson Disease Questionnaire (PDQ) scores (SMD –0.28, 95% CI –0.74 to 0.17), EQ-5D utility (MD 0.10, 95% CI –0.24 to 0.44), or Falls Efficacy Scale–International (FES-I) scores (MD –0.04, 95% CI –1.10 to 1.02). Prediction intervals frequently crossed the null, suggesting effects may vary by setting and population. CONCLUSIONS Wearable device interventions for Parkinson disease produced a small improvement on average in stride length, with no consistent benefits for other gait outcomes, balance, or patient-centered outcomes. By integrating ICF mapping with Hartung-Knapp meta-analysis, prediction intervals, and GRADE, and avoiding pooling of conceptually distinct gait measures used in prior reviews, this review clarifies where evidence is most consistent, supports using wearables as adjuncts to rehabilitation, and underscores the need for larger, longer RCTs with standardized outcomes to determine who benefits and how to implement them. CLINICALTRIAL PROSPERO CRD42024585686; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024585686